SL-901

· Stemline Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SL-901, covering 2025-01-09 to 2025-01-09. Get the full timeline:

Most recent: Clinical Trial Update: Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors [Phase 1]